This linked to the same thread. I was wondering if anyone had any new news. My dad’s oncologist said sometimes keytruda works for a little while then stops. I was hoping to see if anyone else was having experience with this being successful is eliminating evidence of the cancer.
It’s been awhile since I’ve posted here. This news on Keytruda comes at an interesting time for me. I was going to ask how people have done on a chemo regiment of irinotecan, leucovorin and 5-FU. I had first treatment yesterday with at home pump for 5-FU 46 hour drip. I was on regiment of Oxaliplatin and Gemcitobine but that combo was messing with my liver enzymes. My disease right now has metasisized only within my abdominal wall. While meeting with my oncologist, he said he going to apply to Merck to get Keytruda after trying this new chemo combination. Sorry to hear about your Mom, Steven, but thanks for sharing the news on Keytruda.
I’m wondering if anyone knows of specific doctors willing to prescribe Keytruda off label? My mother’s oncologist in Seattle is unwilling because “there’s not enough evidence of efficacy at this time”- in the meantime I cannot find an open trial for keytruda enrolling cholangio patients right now, and I’m panicking a little. We don’t have time to wait 3 or more months for more trials to open. Any information anyone could provide would be appreciated!
Many thanks indeed for posting that and I know that it will be of help and use to many people now and in time to come also. I know that right now things are so very tough for you but please try and take care of yourself, and remember that we are always here for you.
Steven….. Given the circumstances, I did not expect to hear from you so soon. Thanks again, for sharing this important news with us. Your kindness is very much appreciated.
Personally, I believe that the checkpoint signaling pathway involving the programmed death 1 (PD-1) receptor and its ligands ligands PD-L1 and PD-L2 are not yet fully understood. It appears that predictive response not always guarantees it and lack of PD-1 does not exclude response. As always, we have to await the outcome of the clinical research studies.